Key statistics dashboard for Chemomab Therapeutics Ltd. (CMMB). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24.
Stock Data
| Price | $2.65 |
| Market Cap | $16M |
| Beta | 0.58 |
| Exchange | NASDAQ |
| Country | IL |
Valuation Multiples
| P/E Ratio | -2.59 |
| Price / Book | 2.44 |
| P/S | 0.00 |
| P/FCF | -1.45 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 6.41 |
| Quick Ratio | 6.41 |
| Cash Ratio | 3.86 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.00% |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -8.29 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 1.09 |
| Cash per share | 0.84 |
| FCF per share | -1.40 |
| Tangible Book Value per share | 1.09 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 4 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 4 |
| Avg rating (1-5) | 1.00 |
Related companies: BIVI · CANF · CERO · ELAB · GLMD · INM · KZIA
Explore sector: Healthcare · Biotechnology
More sections of CMMB: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks